Home | Back to newsletter main page

Bookmark and Share
Case Comprehensive Cancer Center Newsletter

April 11, 2011

CASE CCC IN THE NEWS

New Cancer Center is a First for Region
Akron Beacon Journal (blog) - Apr 11, 2011
The 120-bed, 10-story facility on the UH Case Medical Center campus includes all the diagnostic and inpatient and outpatient treatment services an adult cancer patient needs under one roof, said Dr. Julian Kim, who recently was named the cancer center's chief medical officer...

UH Cancer Center Unites Care, Eases Capacity Concern
Crain's Cleveland Business - Apr 11, 2011
Dr. Brian Bolwell, the institute's interim chair, said the Clinic was aware of University Hospitals' endeavors but noted that it was important to remain focused on its own progress rather than that of its competitors. "We certainly welcome what other ...

Editing-molecule Mutation Causes Fatal Primordial Dwarfism
EurekAlert (press release) - Apr 7, 2011
In collaboration with Dr. Richard Padgett and other specialists in RNA splicing at the Cleveland Clinic, the team showed that the mutations reduced splicing efficiency by 90 percent. "We are now asking clinicians around the world for samples we can ...

Is Your Child's Headache Actually a Brain Tumor?
Time Magazine - Apr 9, 2011
...First, 50%-60% of all people with brain tumors don't have headaches at all, says [Dr. Gene] Barnett, [director of the Brain Tumor and Neuro-Oncology Center, who treats adults at the Cleveland Clinic]...

UH Seidman Cancer Center to Offer Cutting-edge Care
Cleveland Jewish News - Apr 7, 2011
Dr. Stanton Gerson, Seidman Cancer Center director and coincidently the Seidmans' neighbor, is "immensely gratified" that a 2004 conversation he had with UH CEO Tom Zenty regarding the need for a patient-centered, dedicated cancer hospital has now ...

Study Suggests Wider Role for Neoadjuvant Chemo in Ovarian Cancer
Internal Medicine News Digital Network - Apr 7, 2011
Dr. Peter Rose is a member of the speaker's bureau for Lilly. ORLANDO – Neoadjuvant chemotherapy with interval debulking surgery yields similar overall and longer progression-free survival when compared with primary debulking surgery for women with ...

Today's Health: Radiation dangers
Today's THV - Apr 4, 2011
Dr. John Suh is a radiation oncologist at the Cleveland Clinic. He says you can find radiation almost everywhere. "Radiation is naturally occurring, so it's all around us. So, the ground has radiation. The water that we drink can have very, ...


MARK YOUR CALENDARS

Cancer Center Seminar Series: Development of Targeted Therapy for ERK Pathway in Triple-Negative Breast Cancer
exner

Friday, April 15
12-1 pm
Frohring Auditorium - BRB 105

Please join us Friday, April 15 at the next Cancer Center Seminar Series featuring Chandra Bartholomeusz, MD, PhD. Dr. Bartholomeusz, Assistant Professor of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center, will present Development of Targeted Therapy for ERK Pathway in Triple-Negative Breast Cancer.

Dr. Bartholomeusz has been faculty in the Department of Breast Medical Oncology-Research at the University of Texas MD Anderson Cancer Center since 2009. Her research focuses on the MAPK pathway, particularly the role of ERK in Triple-negative breast cancer, with an emphasis on developing ERK as a therapeutic target for inhibiting tumorigenicity and metastasis. She has used proteomics and siRNA technology to further probe the mechanism of ERK pathway in tumor suppression. These studies will provide a basis for the further understanding of ERK and its implications for the design of more effective targeted therapies. This comprehensive approach will be applied to other groups of interacting genes discovered by siRNA screening during the multifaceted approach in understanding the biological mechanisms to therapeutic interventions.

Special Cancer Center Seminar Series: Thioredoxin-1, a Molecular Switch Modulating TGF-β-mediated Epithelial to Mesenchymal Transition
bartholomeausz

Friday, April 15
1-2 pm
Frohring Auditorium - BRB 105

Immediately following the presentation by Dr. Chandra Bartholomeusz, please join us for a Special Cancer Center Seminar Series featuring Geoffrey Bartholomeusz, PhD, Assistant Professor of Experimental Therapeutics at the University of Texas MD Anderson Cancer Center. Dr. Bartholomeusz will present Thioredoxin-1, a Molecular Switch Modulating TGF-β-mediated Epithelial to Mesenchymal Transition.

Dr. Bartholomeusz's research focuses on understanding the functioning of key signaling pathways such as EGFR, JAK/Stat and Bcr-Abl associated with tumorigenesis in breast, pancreatic and hematopoietic malignancies. His current research focuses on understanding the role of the redox regulator Thioredoxin-1 in tumor proliferation and metastasis. Using a high throughput RNAi screen, he has identified thioredoxin-1 as a component of TGF-beta dependent signaling in both pancreatic and breast cancer cells, and that thioredoxin-1 may function as a modulator of TGF-beta dependent tumor growth and epithelial to mesenchymal transition. His goal is to develop effective targeted therapies of thioredoxin-1 signaling to either inhibit tumor growth and/or inhibit tumor metastasis. His desire to identify small molecules with effective anti-tumor activity has led him to develop a 3D in vitro cell culture model that can be used for high throughput drug screens. His goal is to develop a co-culture 3D model system utilizing either cell lines or primary tumors with the objective of creating a heterogeneous microenvironment for drug screens. His results have been presented nationally and internationally, and have resulted in peer-reviewed publications, including publications in PNAS, Cancer Research, Blood, Journal of Biological Chemistry and Cancer Cell. He is the current recipient of a Cancer Prevention and Research Institute of Texas (CPRIT) Award for 5 years.

Case CCC Scientific Series

The next installment of the Case CCC Scientific Series is scheduled for Thursday, April 21 from 4-6:30 pm in Wolstein Auditorium (WRB 1-413). Drs. Anton Gorbachev, Neetu Gupta and Alex Huang will discuss the topic of Immunology. Presentations will be followed by a short receptions. All are encouraged to attend.

Case CCC Annual Scientific Retreat

The Case CCC Annual Scientific Retreat will be July 8-9 at Corporate College East. Details will be posted soon.


FUNDING OPPORTUNITIES

Pilot Project Grants: American Cancer Society IRG Awards

The Case CCC is currently accepting applications for American Cancer Society Institutional Research Grant (IRG) awards. Pilot funding is available for projects in basic, clinical, prevention and control, behavioral, health services, and epidemiology cancer research with awards up to $30,000 for one-year cancer research projects that provide the basis for future independent grants.

IRG pilot project grants are intended to support independent, self-directed investigators early in their careers (assistant professor or equivalent). Applicants for the pilot project grants should be within 6 years of their first independent research or faculty appointment and eligible to apply for an independent national competitive research grant, but may not currently hold such a grant.

At the time of application, recipients of IRG pilot project grants must be citizens or noncitizen nationals of the United States or its possessions and territories, or must have been lawfully admitted to the United States for permanent residence at the time of application.

Instructions, frequently asked questions, and application forms are available at http://cancer.case.edu. Contact Terri Daso, Cancer Center Administration (844-7252, tld6@case.edu) for more information.

LOI Deadline: June 13
Application Deadline: July 5, 2011

Ovarian Cancer Research Fund

The Ovarian Cancer Research Fund has released a call for applications for the following opportunities:

Program Project Development Grants ($900,000) provide funds for ovarian cancer research projects that may involve several investigators within one institution or collaborations between groups in multiple institutions.

Liz Tilberis Scholars awards ($450,000) are for junior investigators in their first academic faculty appointment. This award is open to physician-scientists (Gynecologic Oncology, Medical Oncology) and PhD scientists.

Ann Schreiber Research Training Programs of Excellence grant ($75,000) funds post-doctoral trainees (Gynecologic Oncology or Medical Oncology fellows or PhDs) who are working in established ovarian cancer research groups.

LOI Deadline: May 9


ANNOUNCEMENTS

NCI Professional Budget Judgement: The Nation's Investment in Cancer Research

As required by statute, each year the NCI prepares for the President and Congress its best professional judgment budget on the optimum funding needed to make the most rapid progress against cancer. The Professional Judgment Budget for 2012, Cancer: Changing the Conversation, is now available on NCI's Web site for public reference. The purpose of this document is to spark a broader conversation about the Nation's investment in cancer research.

Member Sites Selected for Cancer Immunotherapy Trials Network

The Case CCC, with Dr. Pierre Triozzi as PI, is one of 27 sites that will be participating in the new Cancer Immunotherapy Trials Network (CITN). The CITN will conduct multicenter research on agents that boost patients' own immune systems to fight their cancer. By coordinating the efforts of academia, industry, and philanthropic foundations, the CITN is charged with accelerating the development of promising agents that have already been discovered but are not currently used to treat patients with cancer.

An open competition was held for institutions to apply for member site status in the CITN, and immunotherapy experts evaluated candidates on the experience, participation, and collaboration of the investigators and their institutions in immunotherapy trials and their ability to provide laboratory expertise in tumor immunology to support the trials.

An initial meeting of CITN investigators is scheduled for May 9-10 in Bethesda, MD, to discuss the operations of the CITN and to introduce the first concepts to be studied by this new cancer immunotherapy program.

Details are available in the latest NCI Cancer Bulletin.

ACS Grantee Newsletter Winter 2010/2011

The latest edition of the ACS Grantee Newsletter Winter 2010/2011 is now available. Highlights include:

  • Molecular Genetics and Biochemistry of Cancer Program
  • CT Scans Decrease Lung Cancer Death Rates, But Look Before You Leap
  • The Horizon of Hope Campaign and the Longaberger Company Help Women with Breast Cancer
  • Helen Piwnica-Worms, PhD, Named American Cancer Society Research Professor
  • The 'Next Generation' HPV Vaccine
  • Discussion of the Pay-If Program
  • Cancer Facts & Figures for African Americans 2011-2012 Now Available

EVENTS

calendar

**All events are open to anyone interested in attending

April 11

Pathology Research Seminar
Shigemi Matsuyama, PhD
Assistant Professor, Pharmacology
CWRU/UH
Topic: Bax-Mediated Cell Death: Regulation by Non-Bcl-2 Family Proteins
12 pm WRB 5-136

SDIG Meeting
Jihad Skaf, PhD
SOLiD Next Generation Sequencing Specialist
Topic: PostLight Sequencing with Semiconductor Chips: Ion Torrent's Personal Genome Machine
2:30 pm WRB 2-136

Ford Distinguished Lecture
David Mooney, PhD
Professor, Bioengineering
Harvard University
Topic: Programming Cells In Situ with Polymers
4:30 pm WRB 1-413


April 12


April 13

Special Seminar
Nagla Karim, MD, PhD
Assistant Professor, Div. of Medical Oncology
Ohio State University
Topic: Personalized Therapy in Non-small Cell Lung Cancer
8 am Lerner B-151

Pathology Graduate Student Seminar
Kumar Sukhdeo
Rich Lab, Pathology
CWRU/UH
Topic: Identification and Targeting of Chemoresistant Colon Cancer Stem-like Cells Using the LGR5 Surface Receptor
12 pm WRB 5-136

DNA Repair Inhibition Journal Club
Tomas Radivoyevitch, PhD
Assistant Professor, Epidemiology and Biostatistics
CWRU
Topic: A Mathematical Model of AML
2 pm SOM W331

Stem Cell Biology and Regenerative Medicine Seminar
Helmut Kettenmann, PhD
Professor, Cellular Neurobiology
Humboldt University (Berlin, Germany)
Topic: Properties of Microglia and Interaction with Gliomas
2 pm NE1-205 Cleveland Clinic

NCRM Seminar
Hoonkyo Suh, PhD
Assistant Staff, Stem Cell Biology and Regenerative Medicine
Cleveland Clinic
Topic: Neurogenesis-induced Neural Circuit Formation in the Hippocampus
4:30 pm NA5-08 Cleveland Clinic


April 14


April 15

Taussig Cancer Institute Grand Rounds canceled

Hematology/Oncology Fellows
Evi Stavrou, MD
Fellow, Div. of Hem/Onc
CWRU/UH
Topic: Novel Activities in a Murine Factor XII Knockout Model
8 am Wearn 137

Cancer Center Seminar Series
Chandra Bartholomeusz, MD, PhD
Assistant Professor, Breast Medical Oncology-Research
University of Texas MD Anderson Cancer Center
Topic: Development of Targeted Therapy for ERK Pathway in Triple-Negative Breast Cancer
12 pm BRB 105

Immunology Faculty Research in Progress Series
Trine Jorgensen, PhD
Assistant Staff, Immunology
Cleveland Clinic
Topic: Autoimmunity: A Result of Sex- Not Gender
12 pm NE1-205 Cleveland Clinic

Special Cancer Center Seminar Series
Geoffrey Bartholomeusz, PhD
Assistant Professor, Experimental Therapeutics
University of Texas MD Anderson Cancer Center
Topic: Thioredoxin-1, A Molecular Switch Modulating TGF-β-mediated Epithelial to Mesenchymal Transition
1 pm BRB 105

Cancer Center Research in Progress Seminar
David Wald, MD, PhD
Assistant Professor, Pathology
CWRU/UH
Topic: Preferential Targeting of p53-null Colon Cancer Cells by a Plant-derived Alkaloid
4 pm WRB 3-136

 

Case CCC Calendar

LRI Calendar


UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS

Breast Cancer Detection and Management: Issues for 2011
May 20
Hilton Cleveland East
Brochure

Case CCC Annual Scientific Retreat
July 8-9
Details to follow

ADDITIONAL UPCOMING SEMINARS & EVENTS

Fourth Annual Translational to Clinical (T2C) Wound Care Conference
April 8-9
Ohio Union, Ohio State University, Columbus
Details

Midwest Blood Club 9th Annual Symposium
April 21-22
Cincinnati Children's Hospital Medical Center
Details

2011 Clinical and Translational Research and Education Meeting: ACRT/SCTS Joint Annual Meeting
April 27-29
Omni Shoreham in Washington, DC
Details

Cincinnati Cancer Symposium Series: 2011 Symposium on NF-κB, Cancer, Obesity, and Inflammation
May 1-4
Westin Hotel Cincinnati
Details

4th International Symposium on Cancer Metastasis and the Lymphovascular System
May 12-14
New York City
Details

2nd Annual Department of Medicine Research Day
May 16
12-5 pm
Wolstein Research Building auditorium and lobby
Details

Race for the Place
June 5
Beachwood Place Mall
Details

International Society for Stem Cell Research (ISSCR) Annual Meeting
June 15-18
Toronto, Canada
Details

Cancer Health Disparities Summit 2011
July 13-15
Bethesda North Marriott Hotel in Rockville, Maryland
Details

8th International Conference of the Society for Integrative Oncology: Innovating Integrative Oncology: New Science, New Solutions
November 10-12
InterContinental Hotel Cleveland
Details


NCI CANCER BULLETIN

April 5, 2011

News
Featured Article: Crossing Disciplines to Explore Questions about Cancer

Latest Surveillance Data Show Cancer Cases and Deaths Continue to Decline

Patients Taking Imatinib for CML Have Similar Risk of Death as General Population

Risk of Second Cancer Following Radiation Therapy Is Small

Immunotherapy Targets Pancreatic Tumors from the Outside

Breast Cancer Genomes Sequenced to Study Drug Response

Combination of Two Targeted Cancer Drugs Appears Safe in Early Testing

Test May Detect Mesothelioma at the Earliest Stages

In Depth
Menopausal Estrogen Therapy Benefits and Risks Vary by Age, WHI Analysis Suggests

For People with Rare Skin Cancer Syndrome, Drug Brings Relief and Hope

Genome Study of Multiple Myeloma Opens New Avenues for Research

Featured Clinical Trial: Inhibiting Tumor Angiogenesis in Metastatic Hormone-Refractory Prostate Cancer

Updates
FDA Update

CMS Update

Legislative Update

Notes


PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES

Avon Foundation Breast Cancer Research Program
Cycle 2 LOI Deadline: May 6
Cycle 2 Full Proposal Deadline: July 5

Uniting Against Lung Cancer 2011 Legacy Program for Advances in Lung Cancer Research
Deadline: August 17

Lustgarten Foundation Fall 2011: Basic Research Innovator Awards
Concept Proposal Deadline: September 14
Full Application Deadline: October 31

Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC)
Deadline: Open

AACR Scholar-in-Training Awards - Other Conferences and Meetings
Deadline: Open

International Union Against Cancer (UICC) International Cancer Technology Transfer Fellowships
Application Deadline: Open

NCI Short-Term Scientist Exchange Program
Application Deadline: Open

James S. McDonnell Foundation Collaborative Activity Awards
Application Deadline: Open


NIH BULLETIN – Notices and Funding Opportunities

Re-Issuance of Parent Research Career Development (K) Award Funding Opportunity Announcements (NOT-OD-11-063)

Notice of Intent to Publish a Request for Applications for Cancer Target Discovery and Development (CTDD) Initiative (U01) (NOT-CA-11-010)

NIH/PEPFAR Collaboration for Implementation Science and Impact Evaluation (R01) (RFA-AI-11-003)

Research Education Program for Laboratory Animal Medicine Veterinarians (R25) (RFA-RR-11-003)

Mentored Clinical Scientist Research Career Development Award (Parent K08) (PA-11-193)

Mentored Patient-Oriented Research Career Development Award (Parent K23) (PA-11-194)

Midcareer Investigator Award in Patient-Oriented Research (Parent K24) (PA-11-195)

Mentored Quantitative Research Development Award (Parent K25) (PA-11-196)

NIH Pathway to Independence Award (Parent K99/R00) (PA-11-197)

Produced by:
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
216-844-8317 phone
216-844-7832 fax
gillian.irwin@case.edu

HELP US HELP YOU!

If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!

Send items to gillian.irwin@case.edu.